Sign in
Taking peoplePhase 3

Gene therapy for hearing loss caused by otoferlin gene changes

Tests AAVAnc80-hOTOF gene therapy in people with otoferlin-related hearing loss.

Key facts

Who runs it
Eli Lilly and Company
Where
London, United KingdomSee the siteAlso in 3 other countries, 8 sites
Registry title
Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss
Status
Recruiting
Phase
Phase 3
People taking part
48 people, planned
Started
15 Sept 2023
Expected to end
Dec 2029
Type of study
Interventional, 6 groups
Treatments tested
  • AAVAnc80-hOTOF via Akouos Delivery Device
  • AAVAnc80-hOTOF via Akouos Delivery Device and Precision Delivery Mechanism
Record updated
29 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people of any age with hearing loss in both ears caused by changes in the otoferlin gene. They get a one-time gene therapy, AAVAnc80-hOTOF, placed in one or both ears.

Age
Any age, depending on the study group. Some early groups needed people aged 7 to 17 years or at least two years old.
Sex
All sexes can join.
Disease stage
Profound (Part A) or severe to profound (Parts B, C and D) sensorineural hearing loss in both ears, measured by ABR (a brain response hearing test).
Earlier treatment
No cochlear implant in the ear that gets the gene therapy. No investigational drug in a trial in the 6 months before treatment. No earlier gene therapy trial, except AK-OTOF-101 for Part D. Part D is for people already treated in one ear in this trial.
Biomarker or test result
At least two mutations in the otoferlin gene. Preserved distortion product otoacoustic emissions (DPOAEs), a test showing the inner ear's hair cells still respond to sound.

Main reasons for not taking part

  • Ear infections that keep coming back
  • Abnormal ear structure or other ear problems
  • Health problems that rule out surgery, anesthesia or gene therapy
  • Cochlear implant in the ear to be treated
  • Investigational drug in the past 6 months or any earlier gene therapy trial (except AK-OTOF-101 for Part D)

The registry criteria, word for word

Show all 9 criteriaShow less

Other criteria

  • Criteria for Inclusion:
  • Participants may be of any age, based on Cohort Criteria
  • At least two mutations in the otoferlin gene
  • Clinical presentation of Profound (Part A) or Severe to Profound (Parts B, C, and D) bilateral sensorineural hearing loss as assessed by ABR
  • Preserved distortion product otoacoustic emissions (DPOAEs)
  • Able and willing to comply with all study requirements, including willingness to participate in a separate long term follow-up study after completion of this trial; Criteria for Exclusion:
  • Persistent ear infections, anatomic or other abnormalities of the ear, and/or medical conditions that would contraindicate undergoing surgery, anesthesia, and/or administration of investigational gene therapy
  • Cochlear Implant(s) in the ear(s) to receive AAVAnc80-hOTOF
  • Prior participation in a clinical trial with an investigational drug, within six months prior to administration, or any prior participation in a gene therapy clinical trial (with the exception of AK-OTOF-101 for Part D participants)

Where in United Kingdom

Also in 3 other countries, 8 sites

  • University College LondonLondon, United KingdomContact: Lilly Clinical TrialsNo longer taking part

About the trial

What the trial wants to find out

Part A of this trial evaluated the safety and tolerability of a single surgical administration procedure in one or both ear(s) with one of two dose levels of AAVAnc80-hOTOF (LY888891) and evaluated the Akouos Delivery Device, together with the Precision Delivery Mechanism (as applicable), to safely achieve the intended product performance.

Read full original descriptionShow less

Part B of the trial is an open-label, global expansion phase to confirm the efficacy and safety of one dose level of AAVAnc80-hOTOF administered in one or both ear(s). Part B will also evaluate the Intracochlear Delivery System (IDS), which consists of the Akouos Delivery Device, the Precision Delivery Mechanism, and an off-the-shelf syringe.

Part C is a region-specific expansion phase. Part C participants will receive the same dose level of AAVAnc80-hOTOF as participants in Part B, in one or both ear(s) utilizing the IDS.

Part D is a sequential administration phase that allows participants who received AAVAnc80-hOTOF previously in a single ear to receive AAVAnc80-hOTOF administration in the other ear utilizing the IDS.

The 6 groups in the trial

  • Part A: Cohort 1a and Cohort 1bTreatment being tested

    Cohort 1a: Two participants aged 7 to 17 years old (inclusive) to receive intracochlear administration of AAVAnc80-hOTOF (dose level 1) in the study ear using a sterile, one-time use investigational medical device Cohort 1b: Up to six eligible participants will be enrolled to receive intracochlear administration of AAVAnc80-hOTOF (dose level 1) in the study ear using a sterile, one-time use investigational medical device; the first three participants will be at least two years of age at the time of AAVAnc80-hOTOF administration and the next three participants may be of any age

    Treatment: AAVAnc80-hOTOF via Akouos Delivery Device

  • Part A: Cohort 2Treatment being tested

    Cohort 2: Up to six eligible participants will be enrolled to receive intracochlear administration of AAVAnc80-hOTOF (dose level 2) in the study ear using a sterile, one-time use investigational medical device; the first three participants will be at least two years of age at the time of AAVAnc80-hOTOF administration and the next three participants may be of any age

    Treatment: AAVAnc80-hOTOF via Akouos Delivery Device

  • Part A: Bilateral ExpansionTreatment being tested

    Bilateral Expansion: up to eight eligible participants of any age, and no cochlear implants, may be eligible for enrollment into the Bilateral Expansion Cohort (simultaneous bilateral administration of AAVAnc80-hOTOF).

    Treatment: AAVAnc80-hOTOF via Akouos Delivery Device and Precision Delivery Mechanism

  • Part BTreatment being tested

    Part B: Sixteen participants of any age will be enrolled to receive a single unilateral or bilateral administration of AAVAnc80-hOTOF. Participants with one CI will receive unilateral administration of AAVAnc80-hOTOF, while participants with no CIs will have the choice to receive a unilateral or bilateral administration of AAVAnc80-hOTOF, provided both ears meet eligibility criteria.

    Treatment: AAVAnc80-hOTOF via Akouos Delivery Device and Precision Delivery Mechanism

  • Part CTreatment being tested

    Up to ten eligible participants of any age will be enrolled in a region-specific expansion phase to receive a single unilateral or bilateral administration of AAVAnc80-hOTOF. Participants with one CI will receive unilateral administration of AAVAnc80-hOTOF, while participants with no CIs will have the choice to receive a unilateral or bilateral administration of AAVAnc80-hOTOF, provided both ears meet eligibility criteria.

    Treatment: AAVAnc80-hOTOF via Akouos Delivery Device and Precision Delivery Mechanism

  • Part DTreatment being tested

    Participants of any age may be enrolled into Part D, which is a sequential administration phase that allows participants who received unilateral administration of AAVAnc80-hOTOF in AK-OTOF-101 (Parts A, B, or C) the option to receive dose administration of AAVAnc80-hOTOF in the contralateral ear after completing the Year 1 visit.

    Treatment: AAVAnc80-hOTOF via Akouos Delivery Device and Precision Delivery Mechanism

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Trial of AAVAnc80-hOTOF Gene Therapy in Individuals With Sensorineural Hearing Loss Due to Otoferlin Gene Mutations
Plain-language title
Gene therapy for hearing loss caused by otoferlin gene changesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
29 September 2026